The Rising Influence of Rising Affluence

[DewDiligence]

FDA approves MRK’s Vaxneuvance—(f/k/a V114)—pneumococcal vaccine_for_adults:

https://www.merck.com/news/merck-announces-u-s-fda-approval-of-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-for-the-prevention-of-invasive-pneumococcal-disease-in-adults-18-years-and-older-caused-by-15-serot/

Vaxneuvance will compete against PFE’s Prevnar-20, which was FDA-approved for adults a few weeks ago (#msg-164292101).

This is a very large market that could play out as “winner takes all.” PFE has an edge, IMO.

Please see #msg-164292229 for background info on these products.